Other topics in this section

Hepatitis B: latest news

Hepatitis B resources

  • Hepatitis B

    Hepatitis B virus (HBV) is an infection that can cause severe liver damage, sometimes resulting in death. Hepatitis B is very common around the world, particularly in Africa, the...

    From: Booklets

    Information level Level 2
  • Hepatitis B treatment

    Treatments are available if your immune system does not naturally clear hepatitis B infection. The aims of hepatitis B treatment include stopping HBV reproduction, reducing liver inflammation and...

    From: Booklets

    Information level Level 2
  • Hepatitis vaccinations

    Effective vaccinations are available to protect against hepatitis A and hepatitis B. There is currently no vaccine against hepatitis C. All people with HIV should have these vaccinations unless...

    From: Booklets

    Information level Level 2
  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From: Booklets

    Information level Level 2
  • Hepatitis B

    Hepatitis B is a virus that can cause serious damage to the liver. Hepatitis B is usually transmitted through contact with blood, semen, vaginal fluids,...

    From: Factsheets

    Information level Level 2
  • Hepatitis B

    Hepatitis B is a viral infection that can cause serious or even fatal damage to the liver. The word hepatitis literally means inflammation of the...

    From: HIV treatments directory

    Information level Level 4

Hepatitis B features

Hepatitis B news from aidsmap

More news

Hepatitis B news selected from other sources

  • Interferon-based therapy improves clinical outcomes in hepatitis delta infection

    Patients with hepatitis delta virus infection treated with pegylated interferon alpha were less likely to develop clinical outcomes — like decompensation or hepatocellular carcinoma — compared with patients who received nucleos(t)ide based treatment or no treatment at all, according to a presentation at International Liver Congress.

    22 April 2016 | Healio
  • ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study

    Viral rebound studies showed that CMX157 demonstrates best-in-class duration of activity. Nine days following incubation with HBV, using two different experimental conditions, one at equimolar and one at EC90 concentrations, CMX157 showed two- to three-fold reduced viral rebound compared to TAF.

    30 March 2016 | ContraVir press release
  • J&J signs deal with Chinese company for hepatitis B drug

    The deal with Sino's Chia Tai Tiaqing Pharmaceutical unit includes an immune-stimulating agent that could potentially be combined with antiviral drugs J&J acquired when it purchased Novira Therapeutics in November. Hepatitis B has been difficult to cure because antiviral medicines that block replication of the virus have proved insufficient at clearing it from the blood. J&J and other researchers believe an assault by components of the immune system will be needed as part of a cure.

    08 January 2016 | Reuters
  • I am surviving only on 25 per cent of my liver today: Amitabh Bachchan

    Bollywood megastar Amitabh Bachchan made a startling revelation about surviving only on 25 per cent of his liver today having lost the rest 75 percent to the deadly Hepatitis B virus. Speaking at the launch of media campaign for on Hepatitis, Amitabh Bachchan recollected how he contracted the disease.

    24 November 2015 | The Indian Express
  • HIV Drugs Provide Added Benefit of Protecting Against Hepatitis B Virus

    A cohort study involving 2,400 men who have sex with men has shown that men with HIV who were treated effectively with HIV therapy — defined as no detectable HIV virus in the blood — were the least likely (80 percent less likely) to get infected with HBV over a median follow-up of approximately 9.5 years, compared with men with HIV who were not on HIV therapy or men who had detectable HIV virus while on HIV therapy.

    13 October 2015 | Johns Hopkins Medicine
  • ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®

    The Company believes CMX157's lipid-conjugate design clearly differentiates it from tenofovir DF. ContraVir plans to file an investigational new drug (IND) application for CMX157 to treat HBV before year-end 2015. CMX157 benefits from earlier human studies in volunteers under an IND for HIV. ContraVir is focused on a quick evaluation of CMX157 in a Phase 2 clinical study in patients with hepatitis B which it plans to begin in 2016.

    06 October 2015 | Contravir press release
  • After Curing Hepatitis C, Gilead Works to Vanquish More Viruses

    Gilead Sciences Inc., basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B.

    19 August 2015 | Bloomberg
  • China progresses in hepatitis B vaccination, more treatment effort urged

    China has won praises from WHO after reaching its goal to control hepatitis B infection among children through immunization ahead of schedule, but more effort is urged for its adult patients.

    27 July 2015 | Xinhua
  • Drug Resistance Common Among European Patients With Chronic Hepatitis B

    Rates of lamivudine resistance are high among patients with chronic hepatitis B (CHB) infection across Europe, with many patients developing cross-resistance to entecavir, according to a new report.

    14 July 2015 | Medscape
  • Hepatitis B and C - An Action Plan for Saving Lives in Europe

    Last year, leading experts, institutions, patient organisations and pharmaceutical industry representatives met and agreed that the major recommendations produced between 2011 and 2014 should be compiled into one comprehensive document, to make it easier for policy makers, decision makers, civil society organisations and healthcare institutions to tackle viral hepatitis effectively.

    20 May 2015 | European Liver Patients Association
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.